xRead - September 2022

Wise et al.

Page 396

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE IX.B.10.a. Study

design Study groups Clinical endpoint Conclusion

Cetirizine-pseudoephedrine was more effective than the other arms in improving nasal obstruction, nasal flow, and nasal secretions after controlled pollen exposures.

Combination therapy was significantly more effective then monotherapy in reducing symptoms, including nasal congestion.

TSS Both groups showed significant improvement without significant difference between groups.

Nasal total symptom scores Both groups had a significant improvement in symptoms with no statistically significant difference between groups. Symptoms (total and asthma), PFTs, asthma QOL

Combination therapy significantly reduced symptoms of SAR, asthma symptom scores, and asthma QOL scores.

Nasal congestion symptoms scores were significantly reduced with desloratadine-pseudoephedrine compared to monotherapy.

Symptoms, nasal flow, nasal secretions

TSS (without nasal congestion), nasal congestion score

TSS without nasal congestion, TSS with nasal congestion

1 Cetirizine-pseudoephedrine; 2 Cetirizine; 3 Pseudoephedrine; 4 Placebo

1 Desloratadine-pseudoephedrine; 2 Desloratadine; 3 Pseudoephedrine

1 Loratadine-pseudoephedrine daily;

2 Loratadine-pseudoephedrine twice daily 1 Cetirizine-pseudoephedrine;

2 Loratadine- pseudoephedrine

1 Cetirizine-pseudoephedrine; 2 Placebo

1 Desloratadine-pseudoephedrine; 2 Desloratadine; 3 Pseudoephedrine

Evidence for oral antihistamine and oral decongestant combination therapy for the treatment of allergic rhinitis Study Year LOE Badorrek et al. 1050 2009 1b RCT (n = 49): Grubbe et al. 1462 2009 1b RCT (n = 598): Chen et al. 1464 2007 1b RCT (n = 48): Chiang et al. 1463 2006 1b RCT (n = 51): Nathan et al. 1451 2006 1b RCT (n = 274): Chervinsky et al. 1461

2005 1b RCT (n = 650):

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.